Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
Sponsor: Pontifícia Universidade Católica do Paraná
Summary
The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host disease (cGVHD) that is refractory to corticosteroid treatment. The main questions it seeks to answer are: * Is MesenCell infusion safe in patients with corticosteroid-refractory chronic graft-versus-host disease? * Can MesenCell treatment improve the clinical response and disease control in these patients? Participants will receive one to three intravenous infusions of MesenCell, according to the study protocol and be followed for 12 months after the last MesenCell infusion.
Official title: Use of Bone Marrow-Derived Mesenchymal Stem Cells (Mesencell) for the Treatment of Patients Undergoing Hematopoietic Progenitor Cell Transplantation Who Developed Refractory Moderate or Severe Chronic Graft-versus-Host Disease: A Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-10
Completion Date
2028-10
Last Updated
2026-09-17
Healthy Volunteers
No
Interventions
Mesenchymal Stem Cell Infusion
Administration of Advanced Therapy Medicinal Product in patients with chronic GVHD
Locations (4)
Hospital de Clínicas da Universidade Federal do Paraná
Curitiba, Paraná, Brazil
Pontifícia Universidade Católica do Paraná
Curitiba, Paraná, Brazil
Hospital Nossa Senhora das Graças
Curitiba, Paraná, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil